Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Allspring Global Investments Holdings LLC boosted its stake in Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 798.3% during the third quarter, according to the company in its most recent ...

Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential ...

Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...

On Friday, Accolade Inc (ACCD) stock saw a decline, ending the day at $3.5 which represents a decrease of $-0.08 or -2.23% from the prior close of $3.58. The stock opened at $3.59 and touched a low of ...

On Friday, Aquestive Therapeutics Inc (AQST) stock saw a modest uptick, ending the day at $5.03 which represents a slight increase of $0.11 or 2.24% from the prior close of $4.92. The stock opened at ...